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Response to the Reply on behalf of the
‘Permanent Senate Commission for the
Investigation of Health Hazards of Chemical
Compounds in the Work Area’ (MAK
Commission) by Andrea Hartwig Karlsruhe
Institute of Technology (KIT)
Peter Morfeld1,2*, Joachim Bruch3, Len Levy4, Yufanyi Ngiewih5, Ishrat Chaudhuri6, Henry J. Muranko7,
Ross Myerson8,9 and Robert J. McCunney10,11
Prof. Hartwig commented [1] as chair of the MAK Com-
mission on Morfeld et al. 2015 [2]. We would like to
thank the Commission for commenting on our review.
However, the MAK Commission did not address a num-
ber of important issues raised in our paper:
 Calculation error in the MAK Commission’s
document on GBS1 [3] when using the rule of three
in Pauluhn’s volumetric model (we emphasize that
the comment did not dispute the arithmetical error
lowering Model B’s GBS limit value erroneously
from 2.0 mg/m3 to 0.5 mg/m3).
 Use of an MPPD2 program version in [3] that is
outdated and no longer available to enable to
replicate the MAK Commission’s conclusions.
 Input values in [3] that cannot be reproduced from
the references listed in [3] or are not state-of-the-art.
 Inconsistent use of varying input data by the MAK
Commission in [3] although explicitly specified as
guideline in the same document [3].
In addition, the post-hoc density adaptation cannot be
justified by clearance rates varying with substance density
(so done in [1]) because the MAK Commission applied a
constant clearance rate in all calculations [3], i.e., the rate
was set invariant despite the large variation in substance
densities.
We would like to draw attention again to the adverse
outcome pathway (AOP) used in our paper which we
feel important. Our AOP analysis revealed species-
specific differences on the molecular and cellular level
(see pages 20–26 in [2]).These differences are not con-
sidered in the MAK Commission’s Models A and B [3].
The unique susceptibility of rats to lung overload effects
of GBS indicates that rats alone are not a good model
for the derivation of GBS limit values in humans. Studies
showed that other species, such as mice and hamsters,
reacted differently to GBS compared to rats. Please note
that relevant human data from extensive clinical studies
broadly support our AOP considerations (see pages 19
and 20 in [2]). Epidemiological studies in workers ex-
posed to various types of GBS including coal dust, car-
bon black and TiO2 did not find an excess lung cancer
risk that could be related to workplace exposures (see
pages 16–19 in [2]). These studies indicate that the
mechanism of fibrogenic and tumorigenic effects ob-
served in rats does not necessarily apply to humans and
other species. Epidemiological evidence does not seem
to have been discussed by the MAK Commission in their
documentation [1] for a biological plausibility check of
the derivation of the GBS limit value and GBS cancer
classification.
We still feel that the particle surface area metric
should have been considered by the MAK Commission
as an additional third model in [3] as there is abundant
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published evidence that particle surface area has also been
shown to significantly drive pulmonary effects of GBS.
Similarly, we think it important to note that human
data give no indication of a retarded alveolar clearance
under high exposure conditions as found in coal miners
and feel that the Commission should have given some
consideration to this well-known finding. Thus, the con-
cept of volumetric overload of alveolar macrophages indi-
cated by retarded alveolar clearance is not well supported
by human data as the main mode of action of GBS in dust
exposed workers.
Finally, although we address the errors in the calcula-
tion of the deposition fraction related to Model B in [4],
the authors only validated Model A by two unnamed ex-
perts, not Model B. This validation for Model A is not
relevant for our arguments. The same applies when
Hartwig [1] commented on the “density division” per-
formed in Model A by discussing the density depend-
ence of limit values in Model B.
We would like to state that we are not criticising the
use of translational models per se in such an important
and complex area such as developing a generic approach
to recommending an OEL for GBS. In fact, quite the op-
posite: We very much applaud the use of such models
and in particular, the MAK Commission for advancing
the science in this area but, at the same time, we are
pleading that the output from such translational model-
ling is both reproducible and transparent and uses the
most appropriate input data. In addition, the transla-
tional model should be used together with, rather than
instead of, the most appropriate animal and relevant epi-
demiological finding. Such a weight of evidence ap-
proach based on concordance of findings from differing
but complementary fields will best deliver robust
conclusions.
In the following we address relevant issues in a point-
to-point manner. We cite and number comments from
[1] and respond to these passages.
COMMENT 1 in [1]:
“2. In their opinion, considerable shortcomings were:
 Dimension of lung surface area
 Lung clearance rates
 Particle deposition fractions
 Particle mass and volumetric metrics as opposed to
the particle surface area metric
 Particle density”
RESPONSE 1:
One important issue about Model B is neither men-
tioned nor discussed. See the headline on page 9 in Mor-
feld et al. [2]: “Model B: The standardization by rat lung
mass or rat body weight is varying and inconsistent”. We
concluded on page 10: “Obviously, units are confused
and Morrow’s overload threshold should also refer to a
1 kg rat and, thus, should have been set to 4.2 μl per kg-
rat in equation (7). This correction increases the esti-
mated NOAEC by a factor of 4.2.” Thus, we identified a
relevant error within Model B because the “rule of three”
was applied incorrectly in [4] and, consequently, by the
MAK Commission [3]. The Commission [1] did not ad-
dress this important issue.
COMMENT 2 in [1]:
“… was extrapolated to the human equivalent concen-
tration calculating the NOAE particle dose deposited in
the lung employing the MPPD (multi-path particle dos-
imetry) model Version-V2.0 program. All the input data
for this calculation are given in the appendix of the
MAK documentation and have been justified in detail in
the MAK documentation.”
RESPONSE 2:
We were unable to obtain version 2.0 of this program,
which appears to be outdated and the hyperlinks pre-
sented by the MAK Commission [3] are no longer avail-
able for others to use. Thus, a reader will be unable to
reproduce the calculations because he/she is unable to get
the program version V2.0 that the MAK Commission [3]
applied. However, an updated version (Version 2.11) is
accessible (http://www.ara.com/products/mppd.htm). We
showed that Version 2.11 returns different results than
Version 2.0 when using the input data listed in [3] (see
e.g., Table 4 on page 12 in [2]).We stated on page 11 in
[2]: “We emphasize that a revision of the deposition calcu-
lations in [4] and [3] is needed because the deposition frac-
tions were calculated with an MPPD version (i.e. MPPD
Version 2.0) that is outdated. Hence the calculations of the
MAK Commission are not based on a state of the art tech-
nique. We note that the outdated MPPD Version 2.0 is no
longer publicly accessible to enable an independent re-
viewer to reproduce the results. Fortunately, one of the co-
authors of this review has a copy of the outdated version
which we used for our calculations.”
COMMENT 3 in [1]:
“One approach (Model A) the MAK Commission used
to derive a limit value … To assure that the approach is
correctly described, two experts from two different insti-
tutions have been asked to independently use the model
and the respective input data to calculate the deposited
particle dose. Using the MPPD model and the input data
described in the MAK documentation, both experts de-
rived at the same deposited dose values as described in
the MAK documentation.
Thus, the statement by Morfeld et al. [2] that they
were unable to reproduce the deposited dose is not justi-
fied. Obviously, Morfeld et al. [2] used different input
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data and thus consequently obtained different deposited
doses than the MAK Commission.”
RESPONSE 3:
We note that this is a section addressing Model A.
Thus, Prof. Hartwig’s report [1] on a cross check by two
experts relates only to Model A’s deposition fractions.
Note further that our criticism on wrongly derived de-
position fractions was not directed to Model A but to
Model B. We showed that the deposition fractions used
in Model B cannot be reproduced with the input data
listed in the MAK document. The following headline was
published on page 11 in [2]:“Model B: Deposition fractions
applied in Pauluhn [4] cannot be reproduced with the
MPPD program given MAK’s input data [3]”. See also
Table 4 on page 12 in [2] for details on Model B depos-
ition fractions. Thus, our criticism is on Model B. Hartwig
[1] does not address this important issue about Model B
at all. We demonstrated convincingly that the deposition
fractions used in Model B cannot be reproduced using the
input data listed in [3]. To demonstrate the problem, we
draw the reader’s attention to pages 11 and 13 of [2]. We
discussed the input parameter “Oronasal-Normal Aug-
menter” recommended by the MAK Commission: “We
emphasize that “Oronasal-Normal Augmenter” is a recom-
mendation made in the MAK document ([3], p. 58 and
Appendix)… In contrast, in Pauluhn [4] the breathing pat-
tern chosen was “oronasally breathing humans” (p. 186).
When we, however, interpreted this as the program option
“Oronasal-Mouth Breather”, MPPD 2.0 returned a depos-
ition fraction of 16.4 % identical to that reported in [4].”
Secondly, we documented that Model B calculations did
not use the MAK Committee’s recommendation of an
“inhalability adjustment” for rats: “We can reproduce the
value of 7.5 % published in Pauluhn [4] if we switch off the
“inhalability adjustment” in MPPD 2.0. The MPPD tutor-
ial explains: ‘Choose whether the program should adjust
for inhalability of the aerosol using logistic functions sug-
gested by Menache et al. [5] for small laboratory animals.
For small particles, this inhalability is unity. By default,
adjustment for inhalability is turned off.’ (MPPD 2.11 Tu-
torial 1: Monodisperse for Rat, http://www.ara.com/prod-
ucts/mppd.htm). We surmise that the default option of
the program was used in [4] although use of the “inhal-
ability correction” has been recommended by Oller and
Oberdörster [6] and it is listed by the MAK Commission as
the option to choose ([3], p. 58).” Thus, it is obvious that
the Model B deposition fractions cannot be reproduced
using the input parameters listed in MAK Commission’s
document [3].
COMMENT 4 in [1]:
“The MAK Commission used the value of alveolar
lung surface area of 57.22 m2 for humans; this is the
lung volume at the end of a normal exhalation and can be
determined by mechanical lung function measurements as
the Functional Residual Capacity [7, 8]. The MAK Com-
mission extensively discussed the study of Gehr et al. [9]
and came to the conclusion that the value of Gehr of
143 m2 represents the lung area after maximal inhalation
and is not realistic for workplace conditions. The MAK
Commission states that the value of 57.22 m2 is in the
lower range of the published values [3].
Gehr et al. [9] themselves give an explanation why the
determined alveolar surface area in their study does not
represent the “true” value: “On the other hand it is
known that the epithelial surface (defined in the publica-
tion as surface membrane of alveolar epithelial cells)
does not correspond to the true alveolar surface in the
living air-filled lung; this surface is rather formed by the
air-fluid interface of the surface lining layer which
smoothes the epithelial surface. We have shown on rat
lungs that the “true” alveolar surface available for gas
must be by 25–50 % smaller than the epithelial surface
depending on the level of air space inflation. If this is
taken into consideration the “true” alveolar surface of
the human lungs included in this study is reduced to
70–100 m2…” In their study the lungs were “fully in-
flated to near total lung capacity” and this inflation was
achieved by instilling the fixative in aqueous solution
into the airways. This does not represent the real alveolar
surface area for a lightly working person and therefore this
value was not taken into consideration by the MAK
Commission.”
RESPONSE 4:
We would like to emphasize that the main issue under
discussion about lung surface area is not the absolute
area value for humans but the ratio of lung surface areas
between humans and rats. This is because the lung sur-
face area ratio is used in Model A to translate findings
from experimental rats to workers. Thus, we have to
consider both rat and human surface area data. Firstly,
we showed in Morfeld et al. ([2], page 5) that the rat sur-
face area chosen by the MAK Commission did neither
address the rat strain under discussion (Fischer rats) nor
can the value of the rat lung surface area be reproduced
from the references given in [3]. We note that the MAK
Commission [1] did not address this substantial issue
concerning rat lung surface area data. Secondly, the sur-
face areas should be determined with the same method
to derive a reliable human/rat ratio. If the human data is
normalized to “working conditions” the same must be
done with the rat data. If only human data are adapted
without commensurate adaption of rat data, a bias is in-
troduced in the calculations. Note that the need of such
a correction factor for rats is obvious from the passage
of Gehr et al. [9] cited above in [1].Thus, the approach
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of the MAK Committee is biased. Thirdly, we mentioned
that the data of Gehr et al. [9] are the gold standard rec-
ommended for carrying out such comparisons. Besides,
data are available for the rat strain of interest (Fischer
rats). Note that the MAK Commission employed data
derived from an individual Long Evans rat. The overview
given in Table 2 in [2] showed that an unbiased estimate
of the human/rat ratio based on state-of-the-art methods
is 349, not 193 as applied in [3]. Furthermore, we like to
emphasize that Prof. Hartwig [1] misinterpreted the
cited passage of Gehr et al. [9]. We wrote on page 6 in
Morfeld et al. [2]: “It is clear that Gehr and colleagues
[9] discussed the surface available for gas exchange and
not the epithelial surface. We note that the latter is rele-
vant as the denominator in Model A’s metric. Further-
more, Gehr et al. [9] discussed the variation of the
alveolar surface area in dependence on the air space in-
flation and Gehr’s argument relies on the assumption
mentioned in [9] that the ratio between human and rat
lung surfaces does not vary with air space inflation.
Thus, the derived ratio of 349 remains valid irrespective
of what degree of air space inflation is assumed to define
‘true’ values.”
COMMENT 5 in [1]:
“The average clearance half-time value for humans of
400 days was calculated by Bailey et al. [10] and Kreyling
and Scheuch [11]. The same value was used also for the
derivation of ‘General Threshold of Dust’ [12].
The study of Gregoratto et al. [13] calculates a clear-
ance half-time for humans of 300 days. ‘About 40 % of
an insoluble material deposited in the alveolar-
interstitial region remains sequestered indefinitely and
slowly clears only to the lymph nodes. The remaining
material is cleared with half-time of about 300 days.’
The model is based on studies with long-lived radionu-
clides uranium-238, plutonium-239, americium-241
and cobalt-60. The authors do not state clearly whether
the calculation based on this model is valid for other
insoluble or poorly soluble particles.”
RESPONSE 5:
The material addressed is described in the first sen-
tence of the abstract of Gregoratto et al. [13]: “New in-
formation on particle retention of inhaled insoluble
material …”. And in the introduction the authors said
on page 353: “The highly insoluble nature of the inhaled
material …”. Thus, it is obvious that the calculations
based on these models developed by Gregoratto et al.
[13] apply to poorly soluble dusts (GBS). Gregoratto et
al. [13] wrote on p. 555 on best half-time estimates:
“Equivalently, the best estimates for the transfer rates
from the alveolar compartment to the interstitium and
to the bronchiolar region to be used in the new model
are mI = 0.0010 d−1 and mT = 0.0017 d−1, respectively.”
It follows that for the clearance half times: alveolar to inter-
stitium = ln(2)/0.0010 days−1 = 693 days (about 700 days);
alveolar to bronchial region = ln(2)/0.0017 days−1 = 408 days
(about 400 days); from the alveolar compartment (overall)
= ln(2)/0.0027 days−1 = 257 days (about 255 days). We con-
clude that the half time of 400 days used by the MAK
Commission [3] and presented in Bailey et al. [10] does not
consider the clearance into the interstitium (Dr. Bailey co-
authored the paper by Gregoratto et al. [13]).We note that
the interstitium plays no causal role for GBS effects, nei-
ther in MAK Commission’s Model A nor in Model B. This
is so because MAK Commission’s Models A and B limit all
adverse effects to an interaction of deposited dust with
structures/cells within the alveolar compartment. Thus, in
calculations based on Models A and B we have to consider
the overall clearance rate from the alveolar compartment,
not the clearance rate from the alveolar region to the bron-
chial region. This overall alveolar clearance rate is de-
scribed by a half time of 255 days, not 400 days. A value of
250 days for this overall alveolar clearance half time is sup-
ported additionally by the general allometric scaling pro-
cedure proposed by West et al. [14].
COMMENT 6 in [1]:
“The mean deposition fractions were calculated for
rats and humans by applying the MPPD (multi-path par-
ticle dosimetry) Version-V2.0 program. All the input
data for this calculation are given in the appendix of the
MAK documentation; therefore the approach of the
MAK Commission is transparent and the results should
be easily reproducible.”
RESPONSE 6:
Deposition fractions as used in Model B cannot be
reproduced with the MAK Commission’s input data
given in [3] (see RESPONSE 3). Furthermore, as already
stated above (RESPONSE 2), no reader will be able to
get Version 2.0 because the hyperlinks presented by the
MAK Commission [3] do not lead to this version. We
searched extensively and tried to receive the Version 2.0
from the internet but we failed. This version had been
retracted. Only the updated Version 2.11 is available.
COMMENT 7 in [1]:
“The MAK Commission based the derivation of the
MAK value on the principle that inflammation and par-
ticle retention kinetics are largely driven by the volumet-
ric particle dose. Since phagocytosis of GBP depends
primarily on their size and not on their density, the most
appropriate manner to compare various dusts appears to
be the volume of the material [15].
The data available to the MAK Commission did not
provide values for the surface area of the particles as
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metric. The BET surface area is generally used as a sur-
rogate for particle surface area. However, the issue of sur-
face area measurement in practice is complicated.
Therefore and because it is not known what part of the
BET surface may be the biological/toxicological relevant
particle surface, this parameter was not chosen as a dose
metric by the MAK Commission. Also, according to Borm
et al. [16] the debate between “surface” and “volume”
metric is still ongoing.”
RESPONSE 7:
In our publication [2], we did not advocate the sole
application of the particle surface area metric for the
derivation of the HEC. We criticized the MAK Commis-
sion’s total disregard of the contributing effect of the
retained particle surface area metric to pulmonary ef-
fects despite scientific evidence to the contrary. We
stated on page 16 in [2]: “In summary, based on our
review, retained surface area appears to be a reliable
unifying denominator to assess pulmonary toxicity due to
exposure to GBS. The most critical question to consider
in using translational toxicology with any particulate
substance however, is deciding on which of the many
physico-chemical properties it may possess are most rele-
vant (see Table Three in [17]). Thus, the weight of evi-
dence indicates that no one metric can be applied to all
GBS substances. In particular the findings with BaSO4, a
GBS, challenge the basic assumptions of MAK’s transla-
tional toxicology models. … Thus, the approach of the
MAK Commission which dismisses the particle surface
area metric and does not test which metric is more ap-
propriate under various circumstances appears uncon-
vincing [3].”
COMMENT 8 in [1]:
“According to Morrow and Mermelstein [18] ‘The
volumetric amount of dust available for phagocytosis is
the significant factor in dust overloading: consequently a
correction should be made in comparing dust of high
and low density.’
In general, the retained particle dose is determined
through the deposited particles minus the particles which
are taken up by the macrophages and have been carried
away. The highest inhaled particle mass below overload is
6 % of the macrophage volume, which is considered as
NOAEC. The deposited particle mass on the lung surface
takes a certain volume, depending on the density. From
this particle volume the macrophages can only phagocyt-
ose a portion which will fill up 6 % of their volume. Be-
cause the particle mass of TiO2 with a density of 4.3
represents a different particle volume at NOAEC than the
particle volume of a particle with the density of 1, the 6 %
of macrophage volume will contain different masses of
particles depending on their densities. Therefore, at the
same mass concentration (mg/m3) the particles with low
density give rise to higher volume than the particles with
higher density. As a consequence, the particle clearance
and therefore the retained particle dose is not dependent
on the particle density per se but on the particle volume
(Density =mass/volume).”
RESPONSE 8:
The last sentence of the above comment on density is in-
correct and contradicts the logic of Model A as described
in the MAK Commission’s document [3]. The MAK Com-
mission applied alveolar clearance rates invariant of “dens-
ity” and “volume” (given the same species) as we already
have noted on page 5 in [2]: “According to the findings de-
scribed in Bellmann et al. [19], Muhle et al. [20] and Pau-
luhn [4] MAK applied identical elimination half times in
rats of 60 days for toner and TiO2 despite the different dens-
ities of both substances (see for toner equation (5) on page
55 and the calculation for TiO2 on page 57 in [11]). The
implication is that, besides the particle deposition fraction,
particle clearance is also independent of ‘density’.” We note
that this is true in both model applications, A and B: the
half times of alveolar clearance are always set to 60 days in
rats, independently of substance density. This is also made
clear in Prof. Hartwig’s comment [1] on Morfeld et al. [2].
Hartwig [1] wrote above: “For rats the clearance half-time
used is 60 days [15] (see also figure 5 in “General Thresh-
old of Dust” [21].” This is contradictory. A density division
cannot be justified by claiming that clearance rates depend
on substance density whereas the MAK Commission sim-
ultaneously used identical clearance rates for substances
with very different densities.
We emphasize that our criticism of the post-hoc “dens-
ity correction” is related to Model A only. Note that
Model A is a retained particle mass per alveolar surface
area model. It is surprising that Hartwig [1] discussed vol-
ume Model B in this section. We acknowledged that
Model B leads to a density dependent limit: “We note that
in contrast to Model A, the particle density is a necessary
term in this equation, and HECs derived by Model B will
be density dependent” ([2], page 8). Importantly, we have
shown that the logic of Model A is incompatible with a
“density adjustment” of the derived HECs. See pages 4
and 5 in [2] for a detailed demonstration of MAK’s errors
and note the headline: “Model A: Inconsistent post-hoc
density adjustment”. The MAK Commission [1] did not
respond to this critical issue of Model A.
COMMENT 9 in [1]:
“Altogether, the MAK proposal of an OEL for GBP
has been discussed comprehensively, taking into account
all available epidemiological, experimental and mechan-
istic data, a scientific procedure always applied by the
MAK Commission to substances under evaluation.”
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RESPONSE 9:
We are unable to comment on this point as such dis-
cussions, which no doubt will have taken place, were
not included in the MAK Commission’s Documentation
[1]. However, to address this critical issue we presented
sections on epidemiology and exposure data in [2]. We
concluded on page 19: “In summary, no causative link
between exposure to well-investigated respirable GBS
(including some nanostructured dusts) such as coal
mine dust, TiO2, toner or CB and no excess in lung can-
cer risk in humans has been demonstrated.” We added
on page 27: “As reported in the Section on epidemiology
above, no cancer excess risk has been found under these
exposure conditions. It appears that the use of epidemio-
logical evidence should be considered in the derivation of
occupational exposure limits like those of GBS. This may
also help to define the most relevant dust metric for the
measurement of work environment exposures.”
Endnotes
1granular biopersistent dust without known specific
toxicity
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